These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 38025709

  • 1. Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
    Huang Q, Feng D, Pan L, Wang H, Wu Y, Zhong B, Gong J, Lin H, Fei X.
    PeerJ; 2023; 11():e16352. PubMed ID: 38025709
    [Abstract] [Full Text] [Related]

  • 2. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
    Qian K, Xu J, Wan H, Fu F, Lu J, Lin Z, Liu Z, Liu H.
    Gene; 2015 Sep 15; 569(2):173-81. PubMed ID: 26071134
    [Abstract] [Full Text] [Related]

  • 3. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.
    Fang P, Cai D, Du L, Shen F, Zhang C, Li M.
    Clin Appl Thromb Hemost; 2021 Sep 15; 27():10760296211029720. PubMed ID: 34189940
    [Abstract] [Full Text] [Related]

  • 4. Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.
    Zheng C, Li X, Kong C, Ke S, Peng C, Cui T, Gao M, Zhou Y, Guo W, Huang L, Petersen RB, Huang K.
    Blood Coagul Fibrinolysis; 2015 Mar 15; 26(2):185-90. PubMed ID: 25396763
    [Abstract] [Full Text] [Related]

  • 5. Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.
    Xu CW, Wu XB, Ma XL, Wang YS, Zhang BC, Zhao JJ, Wang ZJ, Chen J.
    J Endocrinol Invest; 2012 Jul 15; 35(7):620-4. PubMed ID: 22932273
    [Abstract] [Full Text] [Related]

  • 6. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM, Morelli VM, Matos MF, Lourenço DM.
    Thromb Res; 2014 Jan 15; 133(1):120-4. PubMed ID: 24252537
    [Abstract] [Full Text] [Related]

  • 7. Thrombin-Activatable Fibrinolysis Inhibitor Gene Polymorphism (TAFI1040C/T) in Women With Recurrent Spontaneous Abortion.
    ElDanasori N, Abulata N, Shaheen IA, ElGendy AM, El-Khayat W.
    Clin Appl Thromb Hemost; 2018 Apr 15; 24(3):532-535. PubMed ID: 28301909
    [Abstract] [Full Text] [Related]

  • 8. Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.
    Wang W, Ma H, Lu L, Sun G, Liu D, Zhou Y, Tong Y, Lu Z.
    Blood Coagul Fibrinolysis; 2016 Jun 15; 27(4):419-30. PubMed ID: 26656901
    [Abstract] [Full Text] [Related]

  • 9. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
    de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW.
    J Thromb Haemost; 2009 Jun 15; 7(6):919-27. PubMed ID: 19323787
    [Abstract] [Full Text] [Related]

  • 10. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
    Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V.
    Thromb Res; 2018 Nov 15; 171():171-176. PubMed ID: 30321704
    [Abstract] [Full Text] [Related]

  • 11. [Correlation analysis of thrombin-activatable fibrinolysis inhibitor single nucleotide polymorphism with venous thromboembolism].
    Li C, Hou LH, Liu XE, Huang C, Wei XH.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 15; 20(4):949-53. PubMed ID: 22931662
    [Abstract] [Full Text] [Related]

  • 12. A new functional assay of thrombin activatable fibrinolysis inhibitor.
    Guimarães AH, Bertina RM, Rijken DC.
    J Thromb Haemost; 2005 Jun 15; 3(6):1284-92. PubMed ID: 15946219
    [Abstract] [Full Text] [Related]

  • 13. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 14. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 01; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 15. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun 01; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 16. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
    Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T.
    Haematologica; 2009 Jun 01; 94(6):811-8. PubMed ID: 19377074
    [Abstract] [Full Text] [Related]

  • 17. Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.
    Li Y, Zeng Z, Zhao J, Ma G, Cui L, Tao H, Lin Z, Chen Y, Zhao B, Chen Y, Li K.
    Lipids Health Dis; 2014 May 13; 13():80. PubMed ID: 24886076
    [Abstract] [Full Text] [Related]

  • 18. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct 13; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 19. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug 13; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 20. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan 13; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.